At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 170 enrolled
Drug / intervention
AZD1656 +1 moredrug
Likely dose
AZD1656 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
In Brief
A Phase 2 clinical trial evaluating AZD1656 and Placebo for Covid19. Completed, enrolled 170 participants across 30 sites in 3 countries.
Detailed Summary
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesCzechia, Romania, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedAug 2020
Primary CompletionApr 2021
Study CompletionMay 2021
TodayJul 2026
First PostedAug 18, 2020
Enrollment StartAug 12, 2020
Primary CompletionApr 25, 2021
Study CompletionMay 12, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.9 years ago
Interventions
AZD1656drug
50mg film-coated tablets (at daily dose of 100mg BID)
Placeboother
Matched placebo tablets